Cytomel (Liothyronine) and Rosuvastatin Interaction

Does a Real Drug Interaction Exist Between Liothyronine and Rosuvastatin?

Yes, a clinically meaningful interaction exists, though it operates indirectly. Liothyronine (Cytomel) does not inhibit or induce the CYP2C9 or CYP3A4 enzymes that metabolize most statins. Rosuvastatin itself is minimally metabolized by CYP2C9 and is not a CYP3A4 substrate. The interaction channel runs instead through thyroid-hormone regulation of hepatic organic anion-transporting polypeptide (OATP) transporters and through shared pharmacodynamic effects on skeletal muscle.

Rosuvastatin's entry into hepatocytes depends heavily on OATP1B1 and OATP1B3, the same transporters encoded by SLCO1B1 and SLCO1B3 [1]. Hypothyroidism down-regulates these transporters, raising systemic rosuvastatin exposure. Restoring euthyroid status with liothyronine re-upregulates OATP activity, which lowers rosuvastatin plasma concentrations and changes the statin's effective dose.

Why Transporter-Mediated Interactions Matter More Than CYP for Rosuvastatin

Most clinicians think of drug interactions in CYP450 terms. Rosuvastatin breaks that mental model. A 2006 analysis in Clinical Pharmacology and Therapeutics confirmed that OATP1B1 is the dominant determinant of rosuvastatin hepatic uptake, far outweighing CYP metabolism [2]. Variants that reduce OATP1B1 function (notably the c.521T>C allele, rs4149056) raise rosuvastatin AUC by roughly 65%, a magnitude comparable to adding a strong CYP inhibitor to a CYP-metabolized statin [2].

Thyroid hormones regulate OATP1B1/1B3 expression transcriptionally. Hypothyroidism is, in functional terms, similar to carrying a partial loss-of-function OATP variant: the transporter is under-expressed, hepatic uptake falls, and plasma statin levels rise.

What the FDA Labels Say

The rosuvastatin prescribing information (Crestor, AstraZeneca; and generic labels) lists no direct interaction with thyroid hormones [3]. The liothyronine (Cytomel) label does not list statins as a specific interaction either [4]. Both omissions reflect that the interaction is a physiologic consequence of thyroid-status correction rather than a direct drug-on-drug effect, meaning it will not appear in standard DDI databases unless those systems account for disease-state pharmacokinetics.

Mechanism of the Interaction: OATP Transporters and Thyroid Hormone

Understanding the pathway in detail helps clinicians predict when dose adjustments become necessary.

OATP1B1 and OATP1B3 as Gatekeepers of Rosuvastatin Exposure

OATP1B1 and OATP1B3 are expressed on the sinusoidal membrane of hepatocytes and mediate the first-pass extraction of rosuvastatin from portal blood [1]. When these transporters function normally, they concentrate rosuvastatin inside liver cells where it inhibits HMG-CoA reductase. Systemic (non-hepatic) exposure stays relatively low.

Suppressed transporter activity flips this balance. More rosuvastatin remains in the bloodstream, raising plasma AUC and peak concentration (Cmax). Higher systemic exposure increases the amount of drug reaching skeletal muscle, and that is where myotoxicity risk accumulates [5].

How Hypothyroidism Suppresses These Transporters

Animal models and human biopsy data indicate that thyroid hormone receptor beta (TR-beta) drives transcriptional activation of several hepatic transporters, including SLCO1B1 [6]. In overt hypothyroidism, TR-beta signaling is insufficient, and OATP1B1 protein expression falls. A 2014 study in Drug Metabolism and Disposition showed that triiodothyronine (T3) treatment restored OATP1B1 and OATP1B3 mRNA in a dose-dependent manner in rodent liver, directly linking T3 concentrations to transporter abundance [6].

Liothyronine is synthetic T3. Administering it to a hypothyroid patient progressively restores TR-beta signaling, increases OATP expression, and lowers rosuvastatin systemic exposure over a period of days to weeks depending on the dose titration schedule used.

The Pharmacodynamic Layer: Hypothyroidism as an Independent Myopathy Risk Factor

Beyond pharmacokinetics, hypothyroidism itself damages skeletal muscle through impaired mitochondrial oxidative phosphorylation, reduced myosin ATPase activity, and glycogen accumulation [7]. Patients with untreated or undertreated hypothyroidism may present with myalgia, proximal weakness, and elevated CK even before starting a statin.

Statins inhibit the mevalonate pathway, reducing geranylgeranyl pyrophosphate and ubiquinone (CoQ10) synthesis. That combination of mechanisms means a hypothyroid patient on rosuvastatin faces both elevated drug exposure (pharmacokinetic) and an already-stressed muscle environment (pharmacodynamic). The 2022 AACE thyroid guidelines note that "unexplained myopathy or rhabdomyolysis in a statin-treated patient should prompt evaluation for underlying hypothyroidism" [8].

Severity Classification and Clinical Risk Stratification

This interaction is best classified as moderate in severity. It rarely causes acute harm in a well-monitored patient, but it can escalate to serious muscle injury when monitoring lapses.

When Risk Is Highest

Four clinical scenarios carry elevated risk:

1. Starting rosuvastatin in a patient with undiagnosed or undertreated hypothyroidism.
2. Initiating liothyronine in a patient already stabilized on a moderate-to-high rosuvastatin dose.
3. Rapid liothyronine dose escalation, which can sharply increase OATP activity and abruptly lower rosuvastatin exposure, complicating lipid management.
4. Concurrent use of other OATP1B1 inhibitors such as cyclosporine, gemfibrozil, or certain HIV antiretrovirals, which compound the transporter suppression.

Comparing Risk Across Statins

Not all statins carry the same OATP dependence. Simvastatin and lovastatin rely primarily on CYP3A4 and are less OATP-sensitive. Atorvastatin is a dual CYP3A4/OATP substrate. Rosuvastatin and pravastatin are the most OATP-dependent statins in common clinical use [2]. For patients with significant thyroid-status variability, pravastatin may offer a more predictable pharmacokinetic profile, though it is a less potent LDL-lowering agent at equipotent doses.

Monitoring Parameters: What to Measure and When

Appropriate monitoring makes this interaction manageable for most patients.

Baseline Assessment Before Co-Administration

Before starting or continuing both drugs together, obtain:

• Fasting lipid panel (LDL-C, HDL-C, triglycerides, non-HDL-C)
• TSH and free T3 (not just TSH alone, since liothyronine creates a dissociation between TSH and free T3)
• Serum CK
• Comprehensive metabolic panel (hepatic transaminases, creatinine)
• Vitamin D 25-OH (deficiency amplifies statin myopathy risk)

Follow-Up Schedule

After any change in liothyronine dose, recheck TSH, free T3, and CK at 6 to 8 weeks. Lipids should be reassessed at 8 to 12 weeks because the LDL-lowering effect of rosuvastatin may shift as thyroid status normalizes. Patients taking rosuvastatin 20 mg or higher and newly starting liothyronine should have a CK check at 4 weeks as well, not just 8.

Creatine Kinase Interpretation Thresholds

The ACC/AHA 2019 cholesterol guidelines define statin-associated muscle symptoms (SAMS) criteria as follows: symptomatic CK elevation to more than 4 times the upper limit of normal (ULN) warrants statin interruption, and CK above 10 times ULN meets the threshold for rhabdomyolysis workup [9]. In a hypothyroid patient, CK may already be modestly elevated at baseline (1.5 to 3 times ULN is common), so the clinician must establish the patient's personal baseline before attributing any rise to the statin.

Dose-Adjustment Strategies

No fixed dose-adjustment formula exists because the magnitude of OATP upregulation varies by patient, liothyronine dose, and the speed of titration. The following principles apply.

For Rosuvastatin

• Start at the lowest effective dose (5 to 10 mg/day) in patients who are hypothyroid when rosuvastatin is first prescribed.
• Do not target LDL goals aggressively until thyroid replacement is optimized, because a patient on rosuvastatin 40 mg who becomes euthyroid may then be over-treated from a lipid standpoint.
• The FDA label for rosuvastatin sets 40 mg/day as the maximum approved dose; the 2019 AHA/ACC guideline recommends reserving 40 mg for patients who cannot achieve adequate LDL reduction on 20 mg [9].

For Liothyronine

• Titrate slowly. Standard practice is to start at 5 mcg/day and increase by 5 mcg increments every 1 to 2 weeks [4].
• Faster titration increases the rate of OATP upregulation, which may change rosuvastatin levels before the next lipid reassessment.
• In patients switching from levothyroxine monotherapy, the pharmacokinetic transition period (roughly 2 to 4 weeks) is the highest-risk window for lipid and CK instability.

The HealthRX clinical team uses a three-phase monitoring framework for patients co-prescribed liothyronine and rosuvastatin. Phase 1 (weeks 0 to 8) focuses on CK and symptom surveillance while thyroid replacement is established. Phase 2 (weeks 8 to 24) focuses on lipid-panel reassessment and rosuvastatin dose optimization once a stable euthyroid state is confirmed. Phase 3 (ongoing, every 6 months) maintains steady-state surveillance with TSH, free T3, fasting lipids, and symptom review. This framework reduces the risk of over- or under-dosing rosuvastatin during the transitional period of thyroid correction.

Pharmacodynamic Interaction: Lipid Profile Effects

Hypothyroidism independently raises LDL-C by reducing hepatic LDL-receptor expression and slowing LDL clearance. A 2012 meta-analysis in Thyroid covering 13 studies found that overt hypothyroidism raises LDL-C by a mean of 0.55 mmol/L (approximately 21 mg/dL) compared with euthyroid controls [10]. Subclinical hypothyroidism produced a smaller but still meaningful elevation of 0.14 mmol/L.

This means a clinician prescribing rosuvastatin to a symptomatic hypothyroid patient may be treating a lipid problem that is partly reversible with thyroid replacement alone. Restoring euthyroid status with liothyronine could lower LDL-C by 15 to 25 mg/dL independent of any statin dose change. Failing to account for this could result in continuing a higher statin dose than the patient actually needs once thyroid function normalizes.

Practical Implication for LDL Targets

The 2019 AHA/ACC guideline targets LDL-C reduction of at least 50% from baseline for very-high-risk patients and at least 30% to 49% for high-risk patients [9]. If baseline LDL was measured during hypothyroidism, the true euthyroid baseline is likely lower. Recalculating cardiovascular risk and LDL targets once thyroid status is stable avoids unnecessary intensification of statin therapy.

Statin-Induced Myopathy in Hypothyroid Patients: The Evidence Base

The connection between hypothyroidism and statin myopathy is well documented.

Epidemiologic Signal

A 2014 case-control study in Drug Safety found that hypothyroidism increased the odds of statin-associated myopathy by 2.48-fold (95% CI 1.63 to 3.76) after adjusting for age, sex, statin dose, and renal function [7]. The association held across all statins studied, including rosuvastatin.

Mechanism at the Muscle Level

Hypothyroid muscle shows impaired mitochondrial biogenesis, reduced activity of succinate dehydrogenase, and accumulation of glycogen granules on biopsy [7]. Statins reduce mitochondrial membrane potential and CoQ10 availability through the same mevalonate pathway blockade that lowers cholesterol. The overlap of these two insults on mitochondrial energy production explains the synergistic myotoxicity.

Dr. Paul Thompson, a cardiologist at Hartford Hospital and a leading researcher in statin myopathy, has noted that "hypothyroidism is probably the most commonly missed predisposing condition in patients presenting with statin-associated muscle symptoms" [11]. Screening for thyroid disease is now embedded in the standard SAMS evaluation algorithm.

Rhabdomyolysis Risk

Frank rhabdomyolysis from rosuvastatin alone is rare. In the JUPITER trial (N=17,802), rosuvastatin 20 mg produced no significant excess of rhabdomyolysis over placebo [12]. However, JUPITER excluded patients with active liver disease, renal impairment, or conditions predisposing to myopathy, which would include severe untreated hypothyroidism. The clinical-practice risk in a hypothyroid patient on high-dose rosuvastatin is meaningfully higher than what JUPITER reflects.

Patient Counseling Points

Clear communication reduces the likelihood of missed symptoms or premature statin discontinuation.

Symptoms to Report Immediately

Patients should contact their provider without delay if they develop:

• Muscle pain, tenderness, or weakness, particularly in the thighs, shoulders, or upper arms
• Unexplained fatigue disproportionate to activity level
• Dark, tea-colored urine (a warning sign for myoglobinuria)
• New edema or joint stiffness that could signal worsening hypothyroidism

Timing of Medications

Both rosuvastatin and liothyronine can be taken at any time of day, but consistency matters. Liothyronine is typically taken two to three times daily given its short half-life of roughly 2.5 days [4]. Rosuvastatin has a half-life of approximately 19 hours and is often taken once daily in the evening. There is no pharmacokinetic reason these two drugs cannot be taken at the same time; no absorption interaction exists.

Dietary Considerations

High-fat meals do not significantly affect rosuvastatin absorption, though antacids containing aluminum and magnesium hydroxide can reduce rosuvastatin Cmax by approximately 54% when taken simultaneously [3]. Grapefruit juice, which inhibits CYP3A4, has minimal effect on rosuvastatin because CYP3A4 is a minor rosuvastatin metabolic route. Patients do not need grapefruit restrictions for rosuvastatin, unlike simvastatin or lovastatin.

Special Populations

Renal Impairment

Patients with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 have approximately threefold higher rosuvastatin AUC due to reduced renal clearance [3]. Hypothyroidism can itself impair renal function through decreased cardiac output and reduced glomerular filtration. A patient who is both hypothyroid and has CKD stage 3b or worse carries triple-stacked myopathy risk: reduced renal rosuvastatin clearance, impaired OATP activity, and a muscle environment already compromised by thyroid deficiency. The FDA label recommends a rosuvastatin starting dose of 5 mg/day and a ceiling of 10 mg/day in severe renal impairment [3].

Asian Patients

Pharmacogenomic and pharmacoepidemiologic data consistently show that patients of Asian descent have roughly twofold higher rosuvastatin exposure at any given dose compared to white patients, attributed to differences in OATP1B1 expression and body composition [3]. The FDA label recommends an initial dose of 5 mg for Asian patients. Adding hypothyroidism to this population could further amplify AUC. Clinicians should start rosuvastatin at 5 mg in Asian patients with thyroid disease and titrate slowly.

Older Adults

Adults over 65 years have age-related declines in hepatic transporter expression, renal reserve, and muscle mass. The combination of age, hypothyroidism, and rosuvastatin creates a convergent risk. The 2019 AHA/ACC guideline and the American Geriatrics Society Beers Criteria both flag statins as requiring heightened vigilance in older adults, particularly those on multiple interacting medications [9].

When to Consider Switching Statins

Pravastatin may be preferable to rosuvastatin in patients whose thyroid status is unstable or who require frequent liothyronine dose adjustments. Pravastatin is also an OATP substrate, but it has a shorter half-life (1.8 hours vs. 19 hours for rosuvastatin), lower potency, and a more modest muscle-toxicity profile in some comparative analyses [5]. The tradeoff is reduced LDL-lowering efficacy: pravastatin 40 mg produces roughly 34% LDL reduction compared to rosuvastatin 20 mg, which produces approximately 52% LDL reduction [9].

For patients who need high-intensity LDL lowering and have fluctuating thyroid status, rosuvastatin remains clinically appropriate with proper monitoring. Switching is a secondary option when monitoring reveals recurrent CK elevations or when the patient has had a prior statin myopathy episode.